Astellas Pharma (4503) Drug Pipeline

The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness

A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.

Astellas Pharma JP:4503 is currently developing the following drugs: Pf-08634404, Enfortumab Vedotin, Padcev, Sham Surgery, Asp2246, Brain Surgery, Rehabilitation Therapy, Panitumumab, Asp5834, Avacincaptad Pegol, Asp4396, Fezolinetant, Pudexacianinium Chloride, Gemcitabine, Pembrolizumab, Fluorouracil, Docetaxel, Irinotecan, Pemetrexed, Carboplatin, Cisplatin, Leucovorin, Cetuximab, Asp3082, Oxaplatin, Nanoparticle Albumin-Bound-Paclitaxel, Enzalutamide, Zen003694, Talazoparib Plus Enzalutamide, Gemcitabine, Pembrolizumab, Cisplatin, Enfortumab Vedotin, Rc + Plnd, Bocidelpar, Asp1948, Asp8374, Asp1128, Enzalutamide, Androgen Deprivation Therapy, Talazoparib With Enzalutamide, Nivolumab, Docetaxel, Enzalutamide, Prednisone, Rucaparib, Asp5094, Methotrexate Therapy, Gilteritinib, Fludarabine, Cytarabine, Etoposide, Mitoxantrone, G-Csf, Asp4070, Gabapentin Enacarbil, Enzalutamide, Flutamide, Androgen Deprivation Therapy, Ipragliflozin, Insulin Therapy, Insulin, Ipragliflozin, Tamsulosin, Mirabegron, Asp1941, Asp3325, Asp8273 Capsules, Asp8273 Capsules A, Fk949e, Enzalutamide, Leuprolide Open Label, Gilteritinib, Cytarabine, Idarubicin, Enzalutamide, Ipragliflozin, Atg-F, Gilteritinib, Vancomycin, Opt-80. These drug candidates are in various stages of clinical development as the company works toward FDA approval.